August 27, 2019
Dear Kinamed Agents, Reps & Distributors,
The momentum continues to build! In just a couple of weeks since Meneghini’s Cement Penetration study was published in the Journal of Arthroplasty, we’ve seen a significant surge in CarboJet interest from the orthopedic world.
Below are some of the exciting responses we’ve received:
From the Press:
- The Journal of Arthroplasty’s August 17 tweet of the study received positive reactions (likes, comments & retweets): https://twitter.com/JArthroplasty/status/1162802831872708609?s=09
- Healio/ Orthopedics Today (see their “Top Story” today, Aug 27), OTW (Orthopedics This Week), and OrthoWorld all ran stories on the study.
From Surgeons:
- Surgeons at the Medical University of Vienna saw the article last week and were familiar with the concept from past CCJR presentations. They are now requesting an evaluation.
- A surgeon in Mammoth Lakes, California saw the article 2 weeks ago and requested CarboJet (CJ) for cases the following week. Cases went well and product approval is now in committee.
- Surgeons in Phoenix Arizona saw the article and are requesting that the hospital consider approval of CarboJet in addition to the SuperCable request they already had initiated.
- Another Arizona surgeon who tried to get CarboJet approved a couple of years ago and was turned down for “insufficient peer reviewed” clinical support is going to try again now that he’s seen the Meneghini study.
We’ve been so impressed by the feedback to this study, that we are going to make sure that every surgeon in our network sees the study by emailing the press release directly to all surgeons in our mailing list. In business, as in life, it is important to emphasize your strengths and seize the moment when it presents itself. Now is the moment when we can make significant progress towards making CarboJet the NEW STANDARD OF CARE.
Let’s make it happen!
Patrick Miller
Sales & Marketing Manager
Kinamed, Inc.
tel: 1-805-384-2748 x 207
fax: 1-805-384-2792